Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry-Reference-Cited by-同舟云学术

Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry

Published:2019-11-16 Issue:1 Volume:34 Page:89-98
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Kim Hyoun-Ah^ORCID,Lee Eunyoung,Lee Sun-Kyung,Park Yong-Beom,Lee Young Nam^ORCID,Kang Hee Jung,Shin Kichul^ORCID

Funder

Celltrion Healthcare

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s40259-019-00393-y.pdf

Reference45 articles.

1. European Medicines Agency. European Public Assessment Report: Remsima. 2013. https://www.ema.europa.eu/documents/assessment-report/remsima-epar-public-assessment-report_en.pdf. Accessed 05 Feb 2019.

2. McKeage K. A review of CT-P13: an infliximab biosimilar. BioDrugs. 2014;28(3):313–21.

3. Becciolini A, Raimondo MG, Crotti C, Agape E, Biggioggero M, Favalli EG. A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. Drug Des Devel Ther. 2017;11:1969–78.

4. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–12.

5. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–20.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting;Rheumatology and Therapy;2024-03-20

2. Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand;Immunotherapy;2023-10

3. Retention Rate and Safety of Biologic and Targeted Synthetic DMARDs in Patients with RA-Associated Interstitial Lung Disease: A KOBIO Registry Study;BioDrugs;2023-02-09

4. Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study;Frontiers in Medicine;2022-10-06

5. The Korean College of Rheumatology: 40 Years of Public Health Influence;Journal of Rheumatic Diseases;2022-04-01